Skip to main content
Shanghai Universal Biotech Co.,Ltd. logo

Shanghai Universal Biotech Co.,Ltd. — Investor Relations & Filings

Ticker · 301166 ISIN · CNE100005709 LEI · 300300NWFY07TKBPJT10 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 635 across all filing types
Latest filing 2026-05-25 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 301166

About Shanghai Universal Biotech Co.,Ltd.

https://www.univ-bio.com

Shanghai Universal Biotech Co., Ltd. is a comprehensive service provider for life science research, focusing on the distribution of reagents, consumables, and laboratory instruments. The company maintains an extensive product portfolio featuring antibodies, recombinant proteins, ELISA kits, and biochemical reagents sourced from global manufacturers. It operates a specialized e-commerce platform designed to streamline procurement for academic institutions, clinical laboratories, and pharmaceutical research centers. In addition to product supply, the company offers technical support and experimental services, including antibody validation and laboratory outsourcing. By integrating supply chain management with professional technical expertise, it supports various stages of biomedical research, drug development, and diagnostic innovation.

Recent filings

Filing Released Lang Actions
2025年度权益分派实施公告
Notice of Dividend Amount Classification · 93% confidence The document is an announcement by Shanghai Univen Biotech on its 2025 profit distribution (“权益分派实施公告”), detailing the dividend per 10 shares, total amount, record date, ex-dividend date, tax treatments, and payment procedures. It is not the full annual report or earnings release but specifically a dividend distribution notice. This matches the “Notice of Dividend Amount” category.
2026-05-25 Chinese
关于回购股份注销完成暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement detailing the completion of a share repurchase and cancellation, including the number of shares repurchased, cancellation date, share capital change, and impact on shareholding structure. This matches the “Transaction in Own Shares” category, which covers share buybacks and related capital adjustments—not a general regulatory update or dividend notice.
2026-05-22 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement of the 2025 annual general shareholders meeting resolutions, detailing vote tallies and results for each agenda item. It does not include the full annual report or financial statements but provides the official voting outcomes from the AGM. This aligns with the “Declaration of Voting Results & Voting Rights Announcements” category (DVA).
2026-05-19 Chinese
上海市锦天城律师事务所关于上海优宁维生物科技股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 85% confidence The document is a legal opinion letter issued by a law firm on the legality of convening and conducting the 2025 annual shareholders’ meeting, detailing procedural compliance and vote outcomes. It is not the AGM presentation materials (AGM-R), nor a formal Declaration of Voting Results (DVA) standalone notice. It is a compliance/legal certification document and does not fit any specific financial report category. Per the classification rules, this type of regulatory/legal opinion falls under the general Regulatory Filings (RNS) category.
2026-05-19 Chinese
关于回购股份实施完成暨股份变动的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement by Shanghai Youningwei Bio-Technology Co., Ltd. regarding the completion of its share repurchase plan (buyback), including implementation progress, volumes, prices, compliance with exchange rules, and subsequent share capital changes. This matches the definition of a Transaction in Own Shares report (POS).
2026-05-13 Chinese
关于独立董事辞任暨补选独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of independent directors and the nomination of new independent director candidates. It details the reasons for resignation, the process for replacement, and biographical information about the nominees. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board of directors, specifically independent directors. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and it is not a report or a certification, so it is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA).
2026-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.